Polypill for cardiovascular disease prevention.

Polypill for cardiovascular disease prevention.

Bibliographic Details
Main Author:	Dalton, A
Format:	Journal article
Language:	English
Published:	2013

Similar Items

The Concept of the Polypill in the Prevention of Cardiovascular Disease
by: Brandon Wiley, et al.
Published: (2014-04-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
by: Mant, J, et al.
Published: (2021)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
by: Apichard Sukonthasarn, et al.
Published: (2021-03-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
by: J. Masjuan, et al.
Published: (2021-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
by: Samaneh Noroozi, et al.
Published: (2021-04-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
by: Omneya A. Kandil, et al.
Published: (2022-04-01)

Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
by: Keisuke Narita, et al.
Published: (2023-11-01)

The polypill: the solution for prevention of coronary heart disease?
by: Hendarto Natadidjaja
Published: (2016-02-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
by: Lilian Grigorian-Shamagian, et al.
Published: (2021-08-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
by: Lopez-Lopez JP, et al.
Published: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
by: Gunaratne Padma S, et al.
Published: (2011-01-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
by: Siddharth Birla, et al.
Published: (2023-09-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
by: Massimo F. Piepoli
Published: (2005-06-01)

Preventing the progression of climate change: one drug or polypill?
by: Hugh Montgomery
Published: (2017-03-01)

Polypill holds promise for people with chronic disease
by: Jacqui Wise
Published: (2005-12-01)

Polypill" conception in modern cardiology
by: I E Chazova, et al.
Published: (2018-12-01)

Polypill revisited – Unity in diversity
by: Gheorghe-Andrei Dan, et al.
Published: (2020-08-01)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
by: Carlos Aguiar, et al.
Published: (2022-11-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
by: Reza Jahangiri, et al.
Published: (2022-01-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
by: Cordero A, et al.
Published: (2023-07-01)

Three-dimensional printing of flexible polypill
by: Yasir Karkar, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
by: Jowett, S, et al.
Published: (2017)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
by: Sue Jowett, et al.
Published: (2017-01-01)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
by: Zhu LL, et al.
Published: (2023-09-01)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
by: Lopez-Jaramillo P, et al.
Published: (2023-10-01)

Has the polypill finally proven its worth?
by: Treadwell, J
Published: (2019)

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
by: Anubha Agarwal, et al.
Published: (2024-02-01)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
by: José Alejandro Chávez Fernández, et al.
Published: (2023-01-01)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
by: Usherwood Tim, et al.
Published: (2010-08-01)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
by: Virdee, S, et al.
Published: (2013)

Polypill therapy and frailty in elderly: Time to stop treating everything
by: Sunil Kumar, et al.
Published: (2021-04-01)

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.
by: C Raina Elley, et al.
Published: (2012-01-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
by: Hae Won Jung, et al.
Published: (2023-09-01)

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
by: Enrique Gómez-Álvarez, et al.
Published: (2020-08-01)

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
by: PILL Collaborative Group, et al.
Published: (2011-01-01)

Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens
by: Karavasili, Christina, et al.
Published: (2024)

Polypill eligibility and equivalent intake in a Swiss population-based study
by: Julien Castioni, et al.
Published: (2021-03-01)

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
by: José M. Mostaza, et al.
Published: (2022-12-01)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
by: Lilian Grigorian-Shamagian, et al.
Published: (2023-08-01)

Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
by: Lilian Grigorian-Shamagian, et al.
Published: (2023-10-01)